Revolutionizing Biomedical Discoveries: ThinkCyte Secures $32 Million in Series C Funding Round

We are thrilled to announce that ThinkCyte has successfully raised $32 million in its latest funding round, positioning the company for significant growth and innovation in the realm of single-cell analysis. At ThinkCyte, our mission is to empower scientists and biomedical professionals with breakthrough technologies that accelerate biological discoveries and facilitate the development of novel treatments and diagnostics. With a unique integration of advanced hardware, machine learning, and cutting-edge biotechnology, our solutions offer unparalleled insights at the single-cell level, transforming the way research is conducted in laboratories worldwide. The recently secured funds will be strategically allocated to enhance our research and development efforts, allowing us to further refine our proprietary technology and expand our capabilities in the field. In addition, this funding will support the scaling up of our operations to better serve our increasing customer base, which includes academic researchers, pharmaceutical companies, and clinical laboratories focused on precision medicine. With this injection of capital, ThinkCyte is poised to drive forward innovations that will not only accelerate the pace of scientific discovery but also contribute to the development of targeted and effective therapies that can improve patient outcomes. As we embark on this exciting new chapter, we remain committed to our vision of revolutionizing biomedical research and diagnostics through unprecedented access to single-cell insights. Thank you to all our investors for their belief in our mission and for joining us on this transformative journey.